Saved in:
Bibliographic Details
Main Author: Tahir, Bhatti
Format: Recurso digital
Language:English
Published: Zenodo 2025
Subjects:
Online Access:https://doi.org/10.5281/zenodo.15450402
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866902010113032192
author Tahir, Bhatti
author_facet Tahir, Bhatti
contents <p>This study investigates mutations in conserved motifs of the <strong>SARS-CoV-2 nsp12 (RNA-dependent RNA polymerase) </strong>from genomic sequences collected between <strong>January and April 2025 (Q1)</strong></p> <p>Mutations were analyzed in four key functional motifs: <strong>A, C, F, and G </strong>, which are involved in viral replication and known targets for antiviral drugs such as <strong>Remdesivir </strong>, <strong>Molnupiravir </strong>, and <strong>Favipiravir </strong>.</p> <p>Sequences were aligned using <strong>MAFFT </strong>, translated into amino acid sequences, and scanned for mutations at known resistance-associated positions.</p> <p><strong>Findings:</strong></p> <p><br><strong>Motif A (Positions: D614, P621, N623)</strong><br>D614X : Found in multiple isolates<br>P621X : Detected in several sequences<br>N623X : Observed frequently<br>These mutations are located near the active site of RdRp and may affect polymerase efficiency and drug binding. </p> <p><strong>Motif C (Positions: L655, V657)</strong><br>L655X : Found in several sequences<br>V657X : Commonly observed<br>These positions are implicated in Remdesivir resistance in prior studies. </p> <p><strong>Motifs F and G</strong><br>No reliable mutations could be identified due to:</p> <p>Alignment gaps<br>Truncated sequences<br>Poor coverage in motif regions<br>Further analysis with complete sequences is recommended.</p> <p>Potential Implications for Antiviral Drugs<br>Mutations in motifs A and C may reduce efficacy of:<br><em>Remdesivir</em><br><em>Molnupiravir</em><br>Other nucleoside analogs targeting RdRp<br><span><strong>Note:</strong></span> I did this study independently, it is non-clinical research based on publicly available sequence data. No conclusions should be used for diagnosis, treatment, or policy without further validation. </p> <p> </p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_15450402
institution Zenodo
language eng
publishDate 2025
publisher Zenodo
record_format zenodo
spellingShingle Mapping Potential Drug Resistance Mutations in SARS-CoV-2 nsp12 Motifs Q1 2025
Tahir, Bhatti
Remdesivir
Molnupiravir
Drug Resistance
SARS-CoV-2
D614X
P621X
N623X
L655X
V657X
Motif A
Motif C
<p>This study investigates mutations in conserved motifs of the <strong>SARS-CoV-2 nsp12 (RNA-dependent RNA polymerase) </strong>from genomic sequences collected between <strong>January and April 2025 (Q1)</strong></p> <p>Mutations were analyzed in four key functional motifs: <strong>A, C, F, and G </strong>, which are involved in viral replication and known targets for antiviral drugs such as <strong>Remdesivir </strong>, <strong>Molnupiravir </strong>, and <strong>Favipiravir </strong>.</p> <p>Sequences were aligned using <strong>MAFFT </strong>, translated into amino acid sequences, and scanned for mutations at known resistance-associated positions.</p> <p><strong>Findings:</strong></p> <p><br><strong>Motif A (Positions: D614, P621, N623)</strong><br>D614X : Found in multiple isolates<br>P621X : Detected in several sequences<br>N623X : Observed frequently<br>These mutations are located near the active site of RdRp and may affect polymerase efficiency and drug binding. </p> <p><strong>Motif C (Positions: L655, V657)</strong><br>L655X : Found in several sequences<br>V657X : Commonly observed<br>These positions are implicated in Remdesivir resistance in prior studies. </p> <p><strong>Motifs F and G</strong><br>No reliable mutations could be identified due to:</p> <p>Alignment gaps<br>Truncated sequences<br>Poor coverage in motif regions<br>Further analysis with complete sequences is recommended.</p> <p>Potential Implications for Antiviral Drugs<br>Mutations in motifs A and C may reduce efficacy of:<br><em>Remdesivir</em><br><em>Molnupiravir</em><br>Other nucleoside analogs targeting RdRp<br><span><strong>Note:</strong></span> I did this study independently, it is non-clinical research based on publicly available sequence data. No conclusions should be used for diagnosis, treatment, or policy without further validation. </p> <p> </p>
title Mapping Potential Drug Resistance Mutations in SARS-CoV-2 nsp12 Motifs Q1 2025
topic Remdesivir
Molnupiravir
Drug Resistance
SARS-CoV-2
D614X
P621X
N623X
L655X
V657X
Motif A
Motif C
url https://doi.org/10.5281/zenodo.15450402